LUNG CANCER

Jazz moves to drop Zepzelca’s second-line SCLC use after LAGOON misses survival, while first-line maintenance combo remains approved.

During a live event, Millie Das, MD, and participants discussed why the case for adding a CTLA-4 inhibitor in PD-L1–low metastatic NSCLC does not hold uniformly once histology is taken into account.

ASCO updates stage IV NSCLC guidance, adding repotrectinib and zongertinib, with trial-backed dosing and sequencing tips for tumors positive for ROS1 and HER.

Real-world data show Enhertu drives strong responses in HER2-mutant NSCLC, including brain metastases, while highlighting ILD risks and dosing insights.

Responses seen in more than half of treatment-naive patients, including those with low PD-L1 expression, in the TROPION-Lung02 study.

Study aims to lift pathological complete response above the roughly 5% seen with chemotherapy alone in resectable disease.

Danny Nguyen, MD, of City of Hope discusses bringing clinical trials to community oncology practices and the latest advances in lung cancer treatment.

Longer follow-up links ivonescimab plus chemo to stronger survival gains in EGFR-mutant NSCLC worldwide, supporting FDA review after TKI failure.

FDA clears zidesamtinib for previously treated ROS1-positive metastatic NSCLC, showing 44% responses, CNS activity, and manageable safety in ARROS-1 trial.

During a live event, Millie Das, MD, and participants discussed how long-term survival data are reshaping first-line treatment selection for patients with PD-L1–negative metastatic non–small cell lung cancer.

TREASURE trial shows adding thoracic radiotherapy to atezolizumab maintenance in ES‑SCLC boosts fatal toxicity without survival gain.

Phase 3 data show TROP2 ADC sac-TMT plus pembrolizumab extends PFS in PD-L1–negative nonsquamous NSCLC, signaling a new first-line option.

FDA gives full approval to selpercatinib for RET fusion solid tumors, backed by 47% response rate and long-lasting benefit across cancers.

Phase 3 China trial shows B7-H3 ADC risvutatug rezetecan extends survival vs topotecan in relapsed SCLC, signaling a promising new option.

TRIPLEX finds thoracic radiotherapy with durvalumab chemo in ES-SCLC adds toxicity and deaths, without boosting survival.

LAURA trial safety update shows osimertinib after chemoradiotherapy in stage III EGFR-mutant NSCLC stays manageable, no new signals.

Ateganosine (THIO) plus cemiplimab shows 90.5% disease control in heavily pretreated NSCLC in phase 2 THIO-101 trial interim data (NCT05208944).

The next-generation KRAS G12C inhibitor improved survival vs the approved first-generation agents sotorasib and adagrasib.

ASCO 2026 data reshapes lung cancer care, highlighting durable ALK control, new EGFR options, bispecific first-line gains, and SCLC progress.

The investigational ADC sigvotatug vedotin missed the primary OS endpoint vs docetaxel in phase 3 NSCLC trial, but showed stronger second-line benefit trends.

Dr Haigentz breaks down 3 practice-changing ASCO 2026 lung cancer abstracts, from adjuvant targeted therapy to ADCs reshaping the immunotherapy backbone.

How young women with lung cancer face stigma, misdiagnosis, and fertility gaps—plus the equity-driven approach reshaping care and trials.

Real-world claims data show alectinib beats crizotinib in ALK+ NSCLC survival, urging early use of newer ALK inhibitors.

During a live event, Bruna Pellini, MD, and participants discussed frontline treatment selection for patients with ROS1-positive advanced non–small cell lung cancer, including how evolving efficacy and tolerability data are shifting practice toward newer-generation TKIs.

Topline data show no overall survival advantage for lurbinectedin monotherapy or combination therapy over investigators' choice in second-line metastatic small cell lung cancer; drug's first-line maintenance approval remains intact.